This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lawrence J. Kukla, MD; Donald Burrows, MD; Linda Bressler, Pharm D; William P. McGuire, MD
Chicago

Arch Dermatol. 1981;117(10):604.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Teutsch et al¹ reported a case of Raynaud's phenomenon associated with vinblastine sulfate and bleomycin sulfate chemotherapy for testicular carcinoma. Other possible causes of this process were excluded after the following appropriate studies were done: ESR, antinuclear antibody (ANA), rheumatoid arthritis factor, and cryoglobulins. Bleomycin was suggested as the causative agent of this phenomenon, with the subsequent observation that it occurred after single-agent bleomycin therapy.² However, in another report the effect was attributed to the toxicity of vinblastine.³

We have recently treated a patient in whom the events observed seem to implicate bleomycin as the causative agent of Raynaud's phenomenon.

Report of a Case.—

A 64-year-old man had squamous cell carcinoma of the pharynx and involvement of the cervical lymph nodes bilaterally. The patient was treated with 165 mg of cisplatin (as a 24-hour infusion), 1.6 mg of vincristine sulfate (as an intravenous [IV] . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter     What's this?